• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含D-青霉胺的铁基金属有机框架用于癌症特异性过氧化氢生成及增强化学动力学治疗

Fe-containing metal-organic framework with D-penicillamine for cancer-specific hydrogen peroxide generation and enhanced chemodynamic therapy.

作者信息

Ji Han Bi, Kim Cho Rim, Min Chang Hee, Han Jae Hoon, Kim Se-Na, Lee Cheol, Choy Young Bin

机构信息

Interdisciplinary Program in Bioengineering College of Engineering, Seoul National University Seoul Republic of Korea.

Institute of Medical & Biological Engineering, Medical Research Center, Seoul National University Seoul Republic of Korea.

出版信息

Bioeng Transl Med. 2023 Feb 1;8(3):e10477. doi: 10.1002/btm2.10477. eCollection 2023 May.

DOI:10.1002/btm2.10477
PMID:37206221
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10189484/
Abstract

Chemodynamic therapy (CDT) is based on the production of cytotoxic reactive oxygen species, such as hydroxyl radicals (OH). Thus, CDT can be advantageous when it is cancer-specific, in terms of efficacy and safety. Therefore, we propose NH-MIL-101(Fe), a Fe-containing metal-organic framework (MOF), as a carrier of Cu (copper)-chelating agent, d-penicillamine (d-pen; i.e., the NH-MIL-101(Fe)/d-pen), as well as a catalyst with Fe-metal clusters for Fenton reaction. NH-MIL-101(Fe)/d-pen in the form of nanoparticles was efficiently taken into cancer cells and released d-pen in a sustained manner. The released d-pen chelated Cu that is highly expressed in cancer environments and this produces extra HO, which is then decomposed by Fe in NH-MIL-101(Fe) to generate OH. Therefore, the cytotoxicity of NH-MIL-101(Fe)/d-pen was observed in cancer cells, not in normal cells. We also suggest a formulation of NH-MIL-101(Fe)/d-pen combined with NH-MIL-101(Fe) loaded with the chemotherapeutic drug, irinotecan (CPT-11; NH-MIL-101(Fe)/CPT-11). When intratumorally injected into tumor-bearing mice in vivo, this combined formulation exhibited the most prominent anticancer effects among all tested formulations, owing to the synergistic effect of CDT and chemotherapy.

摘要

化学动力疗法(CDT)基于细胞毒性活性氧的产生,例如羟基自由基(OH)。因此,就疗效和安全性而言,当CDT具有癌症特异性时可能具有优势。因此,我们提出将含Fe的金属有机框架(MOF)NH-MIL-101(Fe)作为铜(Cu)螯合剂d-青霉胺(d-pen;即NH-MIL-101(Fe)/d-pen)的载体,以及用于芬顿反应的具有Fe金属簇的催化剂。纳米颗粒形式的NH-MIL-101(Fe)/d-pen能有效地进入癌细胞并持续释放d-pen。释放出的d-pen螯合在癌症环境中高表达的Cu,这会产生额外的H₂O₂,然后其被NH-MIL-101(Fe)中的Fe分解以生成OH。因此,在癌细胞而非正常细胞中观察到了NH-MIL-101(Fe)/d-pen的细胞毒性。我们还提出了一种NH-MIL-101(Fe)/d-pen与负载化疗药物伊立替康(CPT-11;NH-MIL-101(Fe)/CPT-11)的NH-MIL-101(Fe)联合的制剂。当在体内瘤内注射到荷瘤小鼠体内时,由于CDT和化疗的协同作用,这种联合制剂在所有测试制剂中表现出最显著的抗癌效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/80c652df51b7/BTM2-8-e10477-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/fde86d4a3d49/BTM2-8-e10477-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/c27576366d2b/BTM2-8-e10477-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/201b55d4a0dc/BTM2-8-e10477-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/78e1ca05b009/BTM2-8-e10477-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/30d8a64949fd/BTM2-8-e10477-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/80c652df51b7/BTM2-8-e10477-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/fde86d4a3d49/BTM2-8-e10477-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/c27576366d2b/BTM2-8-e10477-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/201b55d4a0dc/BTM2-8-e10477-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/78e1ca05b009/BTM2-8-e10477-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/30d8a64949fd/BTM2-8-e10477-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c3f/10189484/80c652df51b7/BTM2-8-e10477-g001.jpg

相似文献

1
Fe-containing metal-organic framework with D-penicillamine for cancer-specific hydrogen peroxide generation and enhanced chemodynamic therapy.含D-青霉胺的铁基金属有机框架用于癌症特异性过氧化氢生成及增强化学动力学治疗
Bioeng Transl Med. 2023 Feb 1;8(3):e10477. doi: 10.1002/btm2.10477. eCollection 2023 May.
2
A metal-organic framework (MOF) built on surface-modified Cu nanoparticles eliminates tumors via multiple cascading synergistic therapeutic effects.一种基于表面修饰的铜纳米粒子的金属有机骨架(MOF)通过多种级联协同治疗效应消除肿瘤。
J Colloid Interface Sci. 2024 May 15;662:298-312. doi: 10.1016/j.jcis.2024.02.055. Epub 2024 Feb 9.
3
Metal-Organic Framework-Based Nanoagents for Effective Tumor Therapy by Dual Dynamics-Amplified Oxidative Stress.基于金属有机框架的纳米制剂通过双重动力学增强的氧化应激实现有效的肿瘤治疗。
ACS Appl Mater Interfaces. 2021 Sep 29;13(38):45201-45213. doi: 10.1021/acsami.1c11032. Epub 2021 Sep 16.
4
A multiphoton transition activated iron based metal organic framework for synergistic therapy of photodynamic therapy/chemodynamic therapy/chemotherapy for orthotopic gliomas.一种多光子跃迁激活的铁基金属有机框架用于原位胶质瘤的光动力疗法/化学动力疗法/化疗协同治疗
J Mater Chem B. 2023 Feb 1;11(5):1100-1107. doi: 10.1039/d2tb02273g.
5
Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine.金属有机骨架材料 NH-MIL-88(Fe) 作为溴莫尼定眼部给药载体。
Acta Biomater. 2018 Oct 1;79:344-353. doi: 10.1016/j.actbio.2018.08.023. Epub 2018 Aug 19.
6
Metal-organic framework for biomimetic nitric oxide generation and anticancer drug delivery.用于仿生一氧化氮生成和抗癌药物递送的金属有机框架。
Biomater Adv. 2023 Feb;145:213268. doi: 10.1016/j.bioadv.2022.213268. Epub 2022 Dec 23.
7
[Activating Efficiency of Iron-copper Bimetallic Organic Framework MIL-101(Fe,Cu) Toward H O for Degradation of Dyes].[铁铜双金属有机框架材料MIL-101(Fe,Cu)对H₂O₂降解染料的活化效率]
Huan Jing Ke Xue. 2020 Oct 8;41(10):4607-4614. doi: 10.13227/j.hjkx.202003024.
8
A Smart Near-Infrared Carbon Dot-Metal Organic Framework Assemblies for Tumor Microenvironment-Activated Cancer Imaging and Chemodynamic-Photothermal Combined Therapy.一种智能近红外碳点-金属有机骨架组装体用于肿瘤微环境激活的癌症成像和化学动力学-光热联合治疗。
Adv Healthc Mater. 2022 Jun;11(12):e2102759. doi: 10.1002/adhm.202102759. Epub 2022 Feb 24.
9
One-for-all intelligent core-shell nanoparticles for tumor-specific photothermal-chemodynamic synergistic therapy.用于肿瘤特异性光热-化学动力学协同治疗的通用型智能核壳纳米颗粒
Biomater Sci. 2021 Feb 7;9(3):1020-1033. doi: 10.1039/d0bm01734e. Epub 2020 Dec 16.
10
Doxorubicin-Loaded Metal-Organic Framework Nanoparticles as Acid-Activatable Hydroxyl Radical Nanogenerators for Enhanced Chemo/Chemodynamic Synergistic Therapy.负载阿霉素的金属有机框架纳米颗粒作为酸激活的羟基自由基纳米发生器用于增强化学/化学动力学协同治疗
Materials (Basel). 2022 Jan 30;15(3):1096. doi: 10.3390/ma15031096.

引用本文的文献

1
Cuproptosis: a novel therapeutic mechanism in lung cancer.铜死亡:肺癌中的一种新型治疗机制。
Cancer Cell Int. 2025 Jun 24;25(1):231. doi: 10.1186/s12935-025-03864-1.
2
Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities.癌症中的铜:是友还是敌?代谢、失调及治疗机遇
Cancer Commun (Lond). 2025 May;45(5):577-607. doi: 10.1002/cac2.70005. Epub 2025 Feb 13.
3
A Multifunctional MIL-101-NH(Fe) Nanoplatform for Synergistic Melanoma Therapy.一种用于协同黑色素瘤治疗的多功能MIL-101-NH(Fe)纳米平台。

本文引用的文献

1
Activation of persulfates by ferrocene-MIL-101(Fe) heterogeneous catalyst for degradation of bisphenol A.二茂铁-MIL-101(Fe)非均相催化剂活化过硫酸盐降解双酚A
RSC Adv. 2018 Oct 29;8(64):36477-36483. doi: 10.1039/c8ra07007e. eCollection 2018 Oct 26.
2
Distinguishing chemically induced NADPH- and NADH-related metabolic responses using phasor analysis of UV-excited autofluorescence.利用紫外激发自发荧光的相量分析区分化学诱导的与NADPH和NADH相关的代谢反应。
RSC Adv. 2021 May 24;11(31):18757-18767. doi: 10.1039/d1ra02648h.
3
Nitric Oxide Release and Antibacterial Efficacy Analyses of -Nitroso--Acetyl-Penicillamine Conjugated to Titanium Dioxide Nanoparticles.
Int J Nanomedicine. 2025 Jan 22;20:969-988. doi: 10.2147/IJN.S502089. eCollection 2025.
4
Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.生物医学金属有机框架材料:前景与挑战
Adv Funct Mater. 2023 Nov 21;34(43). doi: 10.1002/adfm.202308589. eCollection 2024 Oct.
5
Cuproptosis: a promising new target for breast cancer therapy.铜死亡:乳腺癌治疗的一个有前景的新靶点。
Cancer Cell Int. 2024 Dec 19;24(1):414. doi: 10.1186/s12935-024-03572-2.
6
Current status and prospects of MIL-based MOF materials for biomedicine applications.用于生物医学应用的基于金属-有机骨架(MIL)的MOF材料的现状与前景
RSC Med Chem. 2023 Sep 1;14(10):1914-1933. doi: 10.1039/d3md00397c. eCollection 2023 Oct 18.
7
Application and Development Prospect of Nanoscale Iron Based Metal-Organic Frameworks in Biomedicine.纳米级铁基金属有机骨架在生物医学中的应用及发展前景。
Int J Nanomedicine. 2023 Sep 1;18:4907-4931. doi: 10.2147/IJN.S417543. eCollection 2023.
- 硝基亚氨乙酰青霉胺修饰的二氧化钛纳米粒子的一氧化氮释放和抗菌效果分析。
ACS Appl Bio Mater. 2022 May 16;5(5):2285-2295. doi: 10.1021/acsabm.2c00131. Epub 2022 Apr 20.
4
Synthesis, characterization, and CO adsorption properties of metal organic framework Fe-BDC.金属有机骨架Fe-BDC的合成、表征及CO吸附性能
RSC Adv. 2021 Jan 28;11(9):5192-5203. doi: 10.1039/d0ra09292d. eCollection 2021 Jan 25.
5
Selective Targeting of Cancer Cells by Copper Ionophores: An Overview.铜离子载体对癌细胞的选择性靶向作用:综述
Front Mol Biosci. 2022 Mar 4;9:841814. doi: 10.3389/fmolb.2022.841814. eCollection 2022.
6
A tumor microenvironment-responsive Co/ZIF-8/ICG/Pt nanoplatform for chemodynamic and enhanced photodynamic antitumor therapy.肿瘤微环境响应型 Co/ZIF-8/ICG/Pt 纳米平台用于化学动力学和增强型光动力抗肿瘤治疗。
Dalton Trans. 2022 Feb 14;51(7):2798-2804. doi: 10.1039/d1dt04120g.
7
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment.基于EPR效应的肿瘤靶向治疗癌症的最新进展
J Pers Med. 2021 Jun 18;11(6):571. doi: 10.3390/jpm11060571.
8
Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.铁和铜细胞内螯合作为一种抗癌药物策略
Inorganics (Basel). 2018;6(4). doi: 10.3390/inorganics6040126. Epub 2018 Nov 30.
9
Hypoxia modulation by dual-drug nanoparticles for enhanced synergistic sonodynamic and starvation therapy.双药物纳米粒子调节缺氧以增强协同声动力和饥饿治疗。
J Nanobiotechnology. 2021 Mar 26;19(1):87. doi: 10.1186/s12951-021-00837-0.
10
Metal-Organic Framework-Integrated Enzymes as Bioreactor for Enhanced Therapy against Solid Tumor via a Cascade Catalytic Reaction.金属有机框架集成酶作为生物反应器,通过级联催化反应增强对实体瘤的治疗
ACS Biomater Sci Eng. 2019 Nov 11;5(11):6207-6215. doi: 10.1021/acsbiomaterials.9b01200. Epub 2019 Nov 1.